RBC Capital Upgrades Pfizer (PFE) to Sector Perform

RBC Capital analyst Trung Huynh upgraded Pfizer (NYSE: PFE) from Underperform to Sector Perform with a price target of $25.00.

The analyst comments: “We upgrade PFE to Sector Perform from Underperform. Our overall thesis has not changed substantially, but the stock is down -11% from highs this year and is now trading in line with our 9x - 1Y fwd PE valuation. We think the risk reward is now more balanced going into two key catalysts: sigvotatug vedotin in 2L lung mid-26, and mevro 2H26. Additionally, strong 1Q26 fundamentals support a potential 2026 guidance upgrade, while the 7% dividend yield should provide a hard floor on downside risk. As such, we move to the sidelines, and reiterate our $25 PT.”

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $25.70 yesterday.

You May Also Be Interested In

• Morgan Stanley Downgrades Healthpeak Properties Inc (DOC) to Equalweight Citing Limited Upside for the Call
• Vox Royalty reports Bonikro mine life extended to 2036 with 120k oz annual output
• Robinhood Markets (HOOD) PT Raised to $97 at Needham